BioSpace News Archive

Deals

CNS Pharmaceuticals Announces Closing Of Initial Public Offering of Common Stock at $4.00 per share

CNS Pharmaceuticals, Inc. announced the closing of its initial public offering of 2,125,000 shares of common stock at an initial public offering price of $4.00 per share.

November 13, 2019
·
2 min read
Business

Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business UpdateConference Call & Webcast Scheduled for Thursday, November 14, at 8:30am Eastern Time

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the quarter ended September 30, 2019 and provided a business update.

November 13, 2019
·
12 min read
Deals

COI Pharmaceuticals Announces Acquisition of Calporta by Merck

COI Pharmaceuticals, the Community Of Innovation established by Avalon Ventures, announced the acquisition of Calporta Therapeutics, Inc. by Merck, known as MSD outside the United States and Canada.

November 13, 2019
·
3 min read
Business

Innate Pharma third quarter 2019 report

Cash, cash equivalents and financial assets of the Company amounted to €215.2 millioni

November 13, 2019
·
12 min read
Deals

PMC Group Announces Agreement to Acquire Lanxess’ Organotin Specialties Business

PMC Group N.A., Inc. and Lanxess Organometallics GmbH are pleased to announce that the parties have reached an agreement whereby PMC’s European subsidiary will acquire the organotin specialties product line from Lanxess.

November 13, 2019
·
2 min read
Verona Pharma to Present at Jefferies 2019 London Healthcare Conference

Verona Pharma plc announces that Jan-Anders Karlsson, CEO of Verona Pharma, will present a corporate overview and host one-on-one meetings with investors at the Jefferies 2019 London Healthcare Conference taking place November 20-21, 2019.

November 13, 2019
·
5 min read
Genetown

PureTech to Present at Jefferies 2019 London Healthcare Conference

PureTech Health plc announced that Daphne Zohar, founder and chief executive officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, at 3:20PM GMT.

November 13, 2019
·
2 min read
Business

Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Initiated pre-screening of patients for Phase 2 ENHANCE-IT study of MAT9001 against Vascepa®. Enrollment to commence Q1 2020, with topline data expected H2 2020

November 13, 2019
·
8 min read
Genetown

ProQR to Present at Upcoming Investor Conferences

ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, announced that Company management will present at upcoming investor conferences

November 13, 2019
·
2 min read
Drug Development

Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program

Study meets its primary endpoint

November 13, 2019
·
5 min read